BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 28669328)

  • 1. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
    Katsiki N; Perez-Martinez P; Anagnostis P; Mikhailidis DP; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):219-227. PubMed ID: 28669328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Critical Approach of Guideline Therapeutic Recommendations for NAFLD.
    Djordjevic DB; Zdravkovic M; Nagorni A; Manolis A; Tsioufis C; Lovic D
    Curr Vasc Pharmacol; 2018; 16(3):228-238. PubMed ID: 28676026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease as a multi-systemic disease.
    Fotbolcu H; Zorlu E
    World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
    Williams T
    FP Essent; 2015 Aug; 435():24-9. PubMed ID: 26280342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Vassilatou E
    World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.
    Kim D; Touros A; Kim WR
    Clin Liver Dis; 2018 Feb; 22(1):133-140. PubMed ID: 29128053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?
    Oikonomou D; Georgiopoulos G; Katsi V; Kourek C; Tsioufis C; Alexopoulou A; Koutli E; Tousoulis D
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):979-985. PubMed ID: 30048367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Simon TG; Corey KE; Chung RT; Giugliano R
    Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.
    Bessone F; Dirchwolf M; Rodil MA; Razori MV; Roma MG
    Aliment Pharmacol Ther; 2018 Nov; 48(9):892-913. PubMed ID: 30194708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of epicardial fat volume and nonalcoholic fatty liver disease with metabolic syndrome: From the CAESAR study.
    Kim BJ; Kim HS; Kang JG; Kim BS; Kang JH
    J Clin Lipidol; 2016; 10(6):1423-1430.e1. PubMed ID: 27919360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance.
    Yang KC; Hung HF; Lu CW; Chang HH; Lee LT; Huang KC
    Sci Rep; 2016 Jun; 6():27034. PubMed ID: 27246655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria.
    Boyraz M; Hatipoğlu N; Sarı E; Akçay A; Taşkın N; Ulucan K; Akçay T
    Obes Res Clin Pract; 2014; 8(4):e356-63. PubMed ID: 25091357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Syndrome in Children and Adolescents: Diagnostic Criteria, Therapeutic Options and Perspectives.
    Weihe P; Weihrauch-Blüher S
    Curr Obes Rep; 2019 Dec; 8(4):472-479. PubMed ID: 31691175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern approach to the clinical management of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
    World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease - A multisystem disease?
    Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
    World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment.
    Kim KS; Lee BW; Kim YJ; Lee DH; Cha BS; Park CY
    Diabetes Metab J; 2019 Apr; 43(2):127-143. PubMed ID: 30993937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.